keyword
MENU ▼
Read by QxMD icon Read
search

Gynecological oncology

keyword
https://www.readbyqxmd.com/read/28346681/obstructive-sleep-apnea-and-postoperative-complications-among-patients-undergoing-gynecologic-oncology-surgery
#1
Olumuyiwa A Bamgbade, Rong R Khaw, Raisah S Sawati, Cathrine M Holland
OBJECTIVE: To investigate the prevalence of obstructive sleep apnea (OSA), physiological or risk factors associated with OSA, and OSA-associated postoperative complications among patients undergoing gynecologic oncology surgery. METHODS: A prospective observational study was done of gynecologic oncology patients undergoing abdominal surgery at a center in the UK between August 2009 and January 2013. All patients underwent perioperative sleep oximetry for the diagnosis of OSA...
March 27, 2017: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/28345826/value-of-sentinel-lymph-node-sln-mapping-and-biopsy-using-combined-intracervical-radiotracers-and-blue-dye-injections-for-endometrial-cancer
#2
Farah Farzaneh, Atefeh Moridi, Zahra Azizmohammadi, Mojtaba Ansari J, Maryam Sadat Hosseini, Maliheh Arab, Tahereh Ashrafganjoei, Mina Mazaheri
Background: Lymphadenectomy, as part of the initial surgical staging of patients with endometrial carcinoma, remains a controversial topic in gynecologic oncology. Sentinel lymph node (SLN) mapping has become a well-accepted procedure for melanomas and breast cancer; a number of investigators have begun to explore the utility and accuracy of this technique with regard to endometrial cancer. Aim: This study was conducted to evaluate SLN mapping of early stage endometrial cancer with blue dye in conjunction with a radioactive tracer...
February 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28341300/a-phase-i-pharmacokinetic-study-of-intraperitoneal-bortezomib-and-carboplatin-in-patients-with-persistent-or-recurrent-ovarian-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#3
Danielle A Jandial, William E Brady, Stephen B Howell, Heather A Lankes, Russell J Schilder, Jan H Beumer, Susan M Christner, Sandra Strychor, Matthew A Powell, Andrea R Hagemann, Kathleen N Moore, Joan L Walker, Paul A DiSilvestro, Linda R Duska, Paula M Fracasso, Don S Dizon
PURPOSE: Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib prior to IP carboplatin increased tumor platinum accumulation resulting in synergistic cytotoxicity. We conducted this phase I trial of IP bortezomib and carboplatin in women with recurrent disease...
March 21, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28338493/surgery-for-recurrent-uterine-cancer-surgical-outcomes-and-implications-for-survival-a-case-series
#4
Lavinia Domenici, Katherine Nixon, Flavia Sorbi, Maria Kyrgiou, Joseph Yazbek, Marcia Hall, Jeremy Campbell, Norma Gibbons, Won-Ho Edward Park, Hani Gabra, Christina Fotopoulou
OBJECTIVE: The purpose of this study was to describe the patterns of relapse in uterine cancer (UC) and the role of surgery in the recurrent setting. METHODS: We describe surgical and clinical outcomes of all patients who underwent surgery for recurrent UC in a gynecological oncology tertiary referral center between May 1, 2013, and April 30, 2016. Progression-free survival and overall survival were estimated using Kaplan-Meier methods with the surgery at relapse being the starting point...
March 23, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28336363/does-surgical-teaching-take-time-resident-participation-in-minimally-invasive-hysterectomy-for-endometrial-cancer
#5
Alexandra H Freeman, Allison Barrie, Liisa Lyon, Carol Conell, Christine Garcia, Ramey D Littell, C Bethan Powell
STUDY OBJECTIVE: To determine the association between resident involvement and operative time for minimally invasive surgery (MIS) for endometrial cancer. DESIGN: Retrospective cohort study DESIGN: Classification: II-2 SETTING: Integrated health care system in Northern California PATIENTS: A total of 1,433 women who underwent MIS for endometrial cancer and endometrial intraepithelial neoplasia from January 2009 to January 2014. INTERVENTIONS: Resident participation in 430/688 laparoscopic cases (62%) and 341/745 robotic cases (46%)...
March 21, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28334914/clinical-utility-of-a-self-administered-questionnaire-for-assessment-of-hereditary-gynecologic-cancer
#6
Kenta Masuda, Akira Hirasawa, Haruko Irie-Kunitomi, Tomoko Akahane, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Hiroyuki Nomura, Fumio Kataoka, Eiichiro Tominaga, Kouji Banno, Nobuyuki Susumu, Daisuke Aoki
Background: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients. Method: Ovarian or endometrial cancer patients were recruited for this study...
December 23, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28334713/pulsed-dose-rate-brachytherapy-for-the-treatment-of-endometrial-cancer
#7
Francesca De Felice, Rossella Caiazzo, Ilaria Benevento, Daniela Musio, Filippo Rubini, Vincenzo Tombolini
Endometrial cancer (EC) is the most frequent gynecologic malignancy. The aim of this review is to outline clinical practice recommendations, to suggest a technical solution, and to advise doses selection for pulsed-dose rate (PDR) brachytherapy in EC. Electronic bibliographic databases, including PubMed, clinicaltrials.gov, and the American Society of Clinical Oncology (ASCO) Meeting Library, were searched for articles in English. Clinical guidelines and systematic reviews were also considered. The appropriate therapeutic approach should consider risk factors for tumor relapse and PDR brachytherapy and have a convincing role in this multidisciplinary scenario...
March 24, 2017: Oncology
https://www.readbyqxmd.com/read/28333228/efficacy-of-ovarian-tissue-cryopreservation-for-fertility-preservation-lessons-learned-from-545-cases
#8
P Jadoul, A Guilmain, J Squifflet, M Luyckx, R Votino, C Wyns, M M Dolmans
STUDY QUESTION: How effective is ovarian tissue cryopreservation (OTC)? SUMMARY ANSWER: In our cohort of patients who underwent OTC, premature ovarian failure (POF) rates, return rates and pregnancy rates after autotransplantation were 31.5, 4.4 and 33%, respectively. WHAT IS KNOWN ALREADY: OTC for fertility purposes has been performed for >20 years now. With over 86 live births reported worldwide and success rates of ~30% after autotransplantation of frozen-thawed ovarian cortex, the procedure should no longer be considered experimental...
March 1, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28327944/a-phase-2-randomized-double-blind-placebo-%C3%A2-controlled-study-of-chemo-immunotherapy-combination-using-motolimod-with-pegylated-liposomal-doxorubicin-in-recurrent-or-persistent-ovarian-cancer-a-gynecologic-oncology-group-partners-study
#9
B J Monk, M F Brady, C Aghajanian, H A Lankes, T Rizack, J Leach, J M Fowler, R Higgins, P Hanjani, M Morgan, R Edwards, W Bradley, T Kolevska, P Foukas, E Swisher, K S Anderson, R Gottardo, J K Bryan, M Newkirk, K L Manjarrez, R S Mannel, R M Hershberg, G Coukos
Background: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death. Patients and methods: Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1 to receive PLD in combination with blinded motolimod or placebo...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28324920/an-open-label-randomized-parallel-phase-ii-trial-to-evaluate-the-efficacy-and-safety-of-a-cremophor-free-polymeric-micelle-formulation-of-paclitaxel-as-first-line-treatment-for-ovarian-cancer-a-korean-gynecologic-oncology-group-study-kgog-3021
#10
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
Purpose: Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here we compared efficacy and safety of Genexol-PM plus carboplatin vs. Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods: In this multicenter, randomized, phase II study, patients with FIGO IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 AUC carboplatin every three weeks (6 cycles)...
March 21, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28316997/sildenafil-can-affect-innate-and-adaptive-immune-system-in-both-experimental-animals-and-patients
#11
REVIEW
Monika Kniotek, Agnieszka Boguska
Sildenafil, a type 5 phosphodiesterase inhibitor (PDE5-I), is primarily used for treating erectile dysfunction. Sildenafil inhibits the degradation of cyclic guanosine monophosphate (cGMP) by competing with cGMP for binding site of PDE5. cGMP is a secondary messenger activating protein kinases and a common regulator of ion channel conductance, glycogenolysis, and cellular apoptosis. PDE5 inhibitors (PDE-Is) found application in cardiology, nephrology, urology, dermatology, oncology, and gynecology. Positive result of sildenafil treatment is closely connected with its immunomodulatory effects...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28314589/fgfr2-mutations-are-associated-with-poor-outcomes-in-endometrioid-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#12
Yvette W Jeske, Shamshad Ali, Sara A Byron, Feng Gao, Robert S Mannel, Rahel G Ghebre, Paul A DiSilvestro, Shashikant B Lele, Michael L Pearl, Amy P Schmidt, Heather A Lankes, Nilsa C Ramirez, Golnar Rasty, Matthew Powell, Paul J Goodfellow, Pamela M Pollock
PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. METHODS: Tumors were collected as part of the GOG 210 clinical trial "Molecular Staging of Endometrial Cancer" where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up...
March 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28304416/gynecologic-malignancies-in-pregnancy-balancing-fetal-risks-with-oncologic-safety
#13
REVIEW
Christina N Cordeiro, Mary L Gemignani
Importance: Cancer occurs in 0.05% to 0.1% of all pregnancies. Despite literature reporting good oncologic and fetal outcomes in women treated for cancer during pregnancy, as many as 44% of gynecologists would offer termination, and 37% would not administer chemotherapy or radiotherapy in pregnancy. Objectives: The aims of this study were to summarize current recommendations for the treatment of cervical and ovarian cancers in pregnancy and to review updates on existing knowledge regarding the safety of surgical and chemotherapeutic treatments in pregnancy, including both oncologic and fetal outcomes...
March 2017: Obstetrical & Gynecological Survey
https://www.readbyqxmd.com/read/28303492/contributions-of-the-japanese-gynecologic-oncology-group-jgog-in-improving-the-quality-of-life-in-women-with-gynecological-malignancies
#14
REVIEW
Masayuki Futagami, Yoshihito Yokoyama, Muneaki Shimada, Shinya Sato, Etsuko Miyagi, Akiko Tozawa-Ono, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Satoru Sagae, Toru Sugiyama
The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28293723/continuous-wound-infiltration-system-for-postoperative-pain-management-in-gynecologic-oncology-patients
#15
Banghyun Lee, Kidong Kim, Soyeon Ahn, Hyun-Jung Shin, Dong Hoon Suh, Jae Hong No, Yong Beom Kim
PURPOSE: Major open surgery for gynecologic cancer usually involves a long midline skin incision and induces severe postoperative surgical site pain (POSP) that may not be effectively controlled with the conventional management. We investigated whether combining a continuous wound infiltration system (CWIS, ON-Q PainBuster(®)) and intravenous patient-controlled analgesia (IV PCA) effectively decreases POSP, compared with IV PCA alone, in gynecologic oncology patients. METHODS: This retrospective study included 62 Korean patients who received a long midline skin incision during gynecologic cancer surgery...
March 14, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28287942/fdg-pet-ct-pitfalls-in-gynecologic-and-genitourinary-oncologic-imaging
#16
Amish Lakhani, Sairah R Khan, Nishat Bharwani, Victoria Stewart, Andrea G Rockall, Sameer Khan, Tara D Barwick
The role of whole-body positron emission tomography (PET)/computed tomography (CT) with fluorodeoxyglucose ( FDG fluorodeoxyglucose ) is now established in the assessment of many gynecologic and genitourinary malignant tumors. FDG fluorodeoxyglucose PET/CT has been widely adopted for staging assessments in patients with suspected advanced disease, in cases of suspected disease recurrence, and for determining prognosis in a number of malignancies. A number of pitfalls are commonly encountered when reviewing FDG fluorodeoxyglucose PET/CT scans in gynecologic and genitourinary cases; these pitfalls can be classified into those that yield potential false-positive or false-negative results...
March 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28285845/a-stratified-randomized-double-blind-phase-ii-trial-of-celecoxib-for-treating-patients-with-cervical-intraepithelial-neoplasia-the-potential-predictive-value-of-vegf-serum-levels-an-nrg-oncology-gynecologic-oncology-group-study
#17
Janet S Rader, Michael W Sill, Jan H Beumer, Heather A Lankes, Doris Mangiaracina Benbrook, Francisco Garcia, Connie Trimble, J Tate Thigpen, Richard Lieberman, Rosemary E Zuna, Charles A Leath, Nick M Spirtos, John Byron, Premal H Thaker, Shashikant Lele, David Alberts
PURPOSE: To examine the effect of celecoxib on cervical intraepithelial neoplasia 3 (CIN 3). This is a NRG Oncology/Gynecologic Oncology Group study with translational biomarkers. PATIENTS AND METHODS: Patients with CIN 3 were randomized to celecoxib 400mg once daily (67 patients) or placebo (63 patients) for 14-18weeks. The primary outcome measure was histologic regression. A test of equal probabilities of success between two therapies was conducted, using Fisher's Exact Test at alpha=10% and 90% power when the treatment arm boosted the probability of success by 30%...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28285537/milestone-clinical-trials-of-the-national-surgical-adjuvant-breast-and-bowel-project-nsabp
#18
REVIEW
Priya Rastogi, D Lawrence Wickerham, Charles E Geyer, Eleftherios P Mamounas, Thomas B Julian, Norman Wolmark
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer through the conduct of large randomized clinical trials evaluating local and systemic therapy. In 2014, the NSABP merged with two other US National Cancer Institute-funded cooperative groups, the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG), to form NRG Oncology. The combined organization has 218 member institutions with more than 600 affiliate centers located throughout the United States, Canada, Puerto Rico, and other international sites...
February 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28283195/effects-of-survivorship-care-plans-on-patient-reported-outcomes-in-ovarian-cancer-during-2-year-follow-up-the-rogy-care-trial
#19
Belle H de Rooij, Nicole P M Ezendam, Kim A H Nicolaije, M Caroline Vos, Johanna M A Pijnenborg, Dorry Boll, Erik A Boss, Ralph H M Hermans, Karin C M Engelhart, Joke E Haartsen, Brenda M Pijlman, Ingrid E A M van Loon-Baelemans, Helena J M M Mertens, Willem E Nolting, Johannes J van Beek, Jan A Roukema, Roy F P M Kruitwagen, Lonneke V van de Poll-Franse
OBJECTIVE: The aim of this study was to assess the long-term impact of an automatically generated Survivorship Care Plan (SCP) on patient reported outcomes in ovarian cancer in routine clinical practice. Outcome measures included satisfaction with information provision and care, illness perceptions and health care utilization. METHODS: In this pragmatic cluster randomized trial, twelve hospitals in the South of the Netherlands were randomized to 'SCP care' or 'usual care'...
March 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28281049/modifiable-and-non-modifiable-characteristics-associated-with-sleep-disturbance-in-oncology-outpatients-during-chemotherapy
#20
Sueann Mark, Janine Cataldo, Anand Dhruva, Steven M Paul, Lee-May Chen, Marilyn J Hammer, Jon D Levine, Fay Wright, Michelle Melisko, Kathryn Lee, Yvette P Conley, Christine Miaskowski
PURPOSE: In a sample of outpatients with breast, gastrointestinal, gynecological, and lung cancer who received at least two cycles of chemotherapy (CTX), the purposes were to evaluate for inter-individual differences in the severity of sleep disturbance and determine which demographic, clinical, and symptom characteristics were associated with initial levels as well as the trajectories of sleep disturbance. METHODS: A total of 1331 patients completed study questionnaires in their homes, at six time points over two cycles of CTX (prior to CTX administration, approximately 1 week after CTX administration, and approximately 2 weeks after CTX administration)...
March 9, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
33838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"